Tag: Lutonix

Ultrascore

CASE REPORT: SFA-CTO Recanalization by using the novel 0.035″ ULTRASCORE Focused...

This case report is sponsored by BD. Ralf Langhoff, chief, Angiology/Vascular Medicine, Sankt Gertrauden-Krankenhaus, Berlin, Germany, reports on a case in which his team used...

Lutonix BTK randomised trial meets safety and efficacy endpoints at six...

Six-month outcomes of a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (BD; DCB) has demonstrated the DCB is safe to use...
Lutonix

Interim results of the Lutonix drug-coated balloon in a complex patient...

This article is sponsored by BD. In a complex patient population with advanced, symptomatic below-the-knee peripheral artery disease, treatment with the Lutonix drug-coated balloon (BD)...

Lutonix Global AV Registry: DCB use prolongs time to reintervention in...

 Tobias Steinke (Dusseldorf, Germany) reported on the Lutonix Global arteriovenous (AV) Registry at CIRSE 2018 in Lisbon, Portugal. Lutonix Global AV Registry data add to...

Latest data on Lutonix and IN.PACT drug-coated balloons in AV access...

There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...

BD announces completion of enrolment in Lutonix 014 DCB below-the-knee trial

Enrolment is complete in the Lutonix below-the-knee trial with BD planning to submit a pre-market approval application to the US Food and Drug Administration...

Bard gets US FDA premarket approval for Lutonix 035 DCB in...

Bard’s Lutonix 035 drug-coated balloon PTA catheter (DCB) has been granted premarket approval (PMA) by the US Food and Drug Administration (FDA) for a...

Lutonix registry data confirm durability of drug-coated balloon treatment in superficial...

The 24-month results of the worldwide experience with Lutonix 035 drug-coated balloon (CR Bard/Beckton Dickenson) were published online in August in JACC: Cardiovascular Interventions....

Lutonix AV results provide tailwind for drug-coated balloons in dysfunctional arteriovenous...

Scott Trerotola presented the first release of eight-month data from the Lutonix AV IDE trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig,...

Lutonix Global Real-World Registry 24-month outcomes presented at VIVA 2016

Bard has announced the presentation of the final 24-month results from the Lutonix Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 meeting...